|
Top Alzheimer's Stocks - Prana Biotechnology (PRAN)
- Prana Biotechnology (PRAN) just released news in September 2011 on a listing in the Journal of Neurochemistry. Prana
Biotech's PBT2 directly restores neurons critical to cognition -
Prana Biotechnology (PRAN) announced that The
Journal Of Neurochemistry has published an update on the mechanism of action of PBT2 in the treatment of Alzheimer's Disease.
The study explains how PBT2 is able to restore cognition in AD sufferers through repair of affected Alzheimer's brains. The
findings further explain the rapid improvement in cognition previously reported in transgenic Alzheimer's mice and in patients
in a Phase IIa clinical trial with PBT2. These new results further explain how PBT2 can achieve rapid improvements in cognition:
by liberation of copper and zinc trapped in amyloid deposits and returning those essential metals to neurons, where they are
needed for normal function.
Prana Biotechnology (PRAN) is an Alzheimers Penny Stock, currently trading around $2.00 per share. If PRAN
can rally above $2.72 in 2011 or 2012, the stock could break out to the $4.00 level.
|
 |
|
|
|
|
|
|
|
|
Alzheimers Stocks to Buy - Forest Laboratories Inc. (FRX)
- Forest Laboratories Inc. (FRX) has an Alzheimers drug called Namenda which is designed to treat moderate to severe cases
of Alzheimers.
The effectiveness of Namenda (memantine hydrochloride) as a treatment for patients with moderate
to severe Alzheimer’s disease was demonstrated in 2 randomized, double-blind, placebo-controlled clinical studies (Studies
1 and 2) conducted in the United States that assessed both cognitive function and day to day function. The mean age of patients
participating in these two trials was 76 with a range of 50-93 years. Approximately 66% of patients were female and 91% of
patients were Caucasian. A third study (Study 3), carried out in Latvia, enrolled patients with severe dementia, but
did not assess cognitive function as a planned endpoint.
Study Outcome Measures: In each U.S. study, the effectiveness
of Namenda was determined using both an instrument designed to evaluate overall function through caregiver-related assessment,
and an instrument that measures cognition. Both studies showed that patients on Namenda experienced significant improvement
on both measures compared
to placebo. Day-to-day function was assessed in both studies using the modified Alzheimer’s
disease
|
|
